Weir, Scott J. http://orcid.org/0000-0002-8020-434X
Dandawate, Prasad
Standing, David
Bhattacharyya, Sangita
Ramamoorthy, Prabhu
Rangarajan, Parthasarathy
Wood, Robyn
Brinker, Amanda E.
Woolbright, Benjamin L.
Tanol, Mehmet
Ham, Tammy
McCulloch, William
Dalton, Michael
Reed, Gregory A.
Baltezor, Michael J.
Jensen, Roy A. http://orcid.org/0000-0003-4430-2281
Taylor, John A. III
Anant, Shrikant http://orcid.org/0000-0003-4193-3053
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA246997, CA246997, CA168524)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 17 February 2021
Revised: 10 May 2021
Accepted: 13 May 2021
First Online: 31 May 2021
Ethics statement
: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The experiments with animals in this study were conducted according to the principles of the Declaration of Helsinki and approved by the Institutional Animal Care and Use Committee of the University of Kansas Medical Center.
: M.T. and S.J.W. are co-inventors of fosciclopirox composition of matter patents issued in the US, Europe, and Japan as well as a methods of use patents issued in the US. S.A. and S.J.W. are inventors on an issued patent in Europe, and a pending application in China. The exclusive, non-terminable rights to intellectual property generated by the inventors, as employees of the University, were licensed by the University of Kansas to CicloMed LLC in 2015. CicloMed is developing fosciclopirox for the treatment of bladder cancer. Kansas Life Sciences Development Company, a subsidiary of the University of Kansas Medical Center Research Institute, Inc. (which is a private, not-for-profit 501(c)(3) corporation established to promote and support medical research and faculty invention disclosures), possesses a financial interest in CicloMed.